Health Canada authorizes updated Novavax COVID-19 vaccine targeting XBB variant
OTTAWA — Health Canada has authorized an updated COVID-19 vaccine from Novavax that targets the XBB.1.5 variant.
The new vaccine is called Nuvaxovid and is approved for people 12 years of age and over.
Nuvaxovid is a protein subunit vaccine, meaning it contains harmless pieces of virus.
The other two XBB vaccines currently authorized in Canada are mRNA vaccines, manufactured by Pfizer-BioNTech and Moderna.